Sydney, June 13, 2026, 04:07 (AEST).
- Telix Pharmaceuticals ended at A$13.60 on June 12, rising 0.97%. The S&P/ASX 200 added 1.98%.
- Investors are eyeing September 11, 2026, when the FDA is set to make a decision on Pixclara, Telix’s imaging drug for brain cancer.
- The stock is well under its 12-month high, so there’s upside left. But regulatory and execution risk remain in focus.
Telix Pharmaceuticals Limited closed at A$13.60 in Sydney, climbing 0.97% after gaining A$0.13 for the day. Shares traded between A$13.32 and A$13.99. The session saw a firm rally in the S&P/ASX 200, which jumped 1.98%. Telix tracked the market higher but trailed the broader advance as investors considered its busy regulatory calendar against improving risk sentiment.
Telix isn’t moving like a typical healthcare defensive. Shares are still trading about 47% under their 12-month high of A$25.75. The stock climbed more than 5% this week, but it’s still seen as exposed to news on clinical trials and market swings in growth names. One day’s gain is less important to investors than whether Telix can turn its pipeline into new approved drugs, beyond its prostate-cancer imaging business.
Telix’s main short-term focus is the FDA review of TLX101-Px, proposed to be sold as Pixclara, for use in PET scans for glioma. PET, or positron emission tomography, relies on radioactive tracers to pick up activity inside the body. The company said the FDA accepted the resubmitted New Drug Application and set a target review date under PDUFA for September 11, 2026. Telix Precision Medicine CEO Kevin Richardson called it “an important milestone for Telix.” The company said its 2026 revenue guidance does not include any Pixclara sales. Telix Pharmaceuticals
Telix bulls point to growth and option value. For the first quarter of 2026, Telix posted unaudited group revenue of US$230 million, up 11% from the previous quarter. The company stuck with its full-year revenue outlook at US$950 million to US$970 million. Precision Medicine revenue climbed 16% versus the prior quarter, helped by Illuccix and Gozellix. CEO Christian Behrenbruch said, “Growth accelerated across our Precision Medicine business” during the quarter. Telix Pharmaceuticals
Telix’s pipeline is keeping investors interested. The company this month shared Part 1 results from its ProstACT Global Phase 3 trial of TLX591-Tx in metastatic castration-resistant prostate cancer, reporting the drug was tolerated by patients in standard-of-care combinations and there were no new safety issues. Telix has begun Part 2 in regions where it’s allowed and said it’s in talks with the FDA about moving ahead with the expansion in the U.S.
The bear camp points to regulatory risk, manufacturing demands, and the bar set by high expectations. Reuters said last year the FDA wanted extra data on Telix’s kidney-cancer imaging drug due to issues in manufacturing and supply chain, and shares slid after the news. That’s a risk for radiopharmaceuticals, which often face tougher rules and more complicated production and transport than typical drugs.
Valuation looks mixed right now. Fourteen analysts on MarketScreener have a “Buy” rating, with an average target price of A$23.32. That’s well above the last close at A$13.60, so there’s room for upside if the company hits key regulatory and commercial milestones. But the spread also points to risk: the price assumes a lot going right. Any stumble—whether missing approvals, slow traction for new imaging products, higher R&D costs, or a manufacturing delay—could hit the multiple fast. MarketScreener
Telix only looks appealing to investors willing to take on biotech regulatory risk. The shares don’t come off as outright cheap for those seeking lower risk. The most watched date is the FDA’s September decision on Pixclara, which could move the stock. A yes from regulators might help Telix’s argument for greater revenue diversity. But if the FDA delays or rejects Pixclara, worries holding the stock below last year’s highs could easily return.
